CV #11: Pharma Lobbying In Ontario — Good Thing Bill 160 Was Never Implemented

1. Other Articles On CV “Planned-emic”

The rest of the series is here. Many lies, lobbying, conflicts of interest, and various globalist agendas operating behind the scenes. The Gates Foundation finances: the World Health Organization, the Center for Disease Control, GAVI, ID2020, John Hopkins University, Imperial College London, the Pirbright Institute, the British Broadcasting Corporation, and individual pharmaceutical companies. Also: there is little to no science behind what our officials are doing; they promote degenerate behaviour; the Australian Department of Health admits the PCR tests don’t work; the US CDC admits testing is heavily flawed; and The International Health Regulations are legally binding. See here, here, and here.

2. Important Links

Bill 160, Ontario Legislative Assembly
About Certain Sections Of Bill 160
CLICK HERE, for Canadian Manufacturing article on Apotex.
http://archive.is/H5OBj
CLICK HERE, for Apotex lobbying Federal Government.
http://archive.is/GnOXR
CLICK HERE, for 2017 legislation to disclose pharma payoffs.
http://archive.is/CRqts
CanLII: Proclamation Never Happened For Bill 160
CLICK HERE, for Ford leaves pharma disclosure law in limbo.
http://archive.is/g1NHC

http://lobbyist.oico.on.ca

Health.Sector.Payment.Transparency.Act20171123_Submission-on-Bill-160_IMC_Final
b160.accountability.ra_e

2. Context For This Article

I would argue that one cannot understand how public officials are reacting to the coronavirus “pandemic” without realizing who is behind the scenes. Among others, pharmaceutical companies (a.k.a Big Pharma) has been sending lobbyists in to have meetings with these officials.

This is of course not unique to Canada. And lobbying (for better of for worse) is a reality of political life. But what needs to be highlighted is the inherent conflict-of-interest when drug companies try to push solutions that they will benefit from.

Never mind that all of their predictions and modelling have been unreliable. Never mind that large numbers of people have recovered, and that deaths have been mis-labelled in order to inflate the casualty count. No, the only thing that matters is developing a vaccine.

In the previous section, several of the articles are devoted to the lobbying that has been ongoing in Canada. The Federal Government, and the Government of Alberta support mass vaccination. A reasonable person searching the lobbying registries may wonder is lobbying from pharmaceutical companies has influenced that attitude.

Now we turn to Ontario. Premier Doug Ford has bragged that there is “no reason a vaccine can’t come from Ontario”. But why is so eager to put out a vaccine on the public? As with before, it seems that the proposed solution may come from who is speaking to, and influencing the government.

Also noteworthy is Bill 160. This is the Health Sector Payment Transparency Act, passed in late 2017 by then Premier Kathleen Wynne. As the name implies, it would have forced pharmaceutical companies to disclose all spending and gifts offered in return for favourable treatment. The Liberals passed the bill, but never formally enacted the measures. It seems that Ford’s Progressive Conservatives never bother to enact it either.

3. Royal Assent On December 12, 2017

  • Ambulance Act
  • Anti-Racism Act, 2017
  • Broader Public Sector Accountability Act, 2010
  • Child and Family Services Act
  • Child, Youth and Family Services Act, 2017
  • City of Toronto Act, 2006
  • Commitment to the Future of Medicare Act, 2004
  • Coroners Act
  • Drug and Pharmacies Regulation Act
  • Electronic Cigarettes Act, 2015
  • Excellent Care for All Act, 2010
  • Freedom of Information and Protection of Privacy Act
  • Healing Arts Radiation Protection Act
  • Health Care Consent Act, 1996
  • Health Facilities Special Orders Act
  • Health Insurance Act
  • Health Protection and Promotion Act
  • Health sector payment transparency act, 2017
  • Independent Health Facilities Act
  • Local Food Act, 2013
  • Local Health System Integration Act, 2006
  • Long-Term Care Homes Act, 2007
  • Medical Radiation and Imaging Technology Act, 2017
  • Medical Radiation Technology Act, 1991
  • Ministry of Health and Long-Term Care Appeal and Review Boards Act, 1998
  • Municipal Act, 2001
  • Occupational Health and Safety Act
  • Ontarians with Disabilities Act, 2001
  • Ontario Drug Benefit Act
  • Ontario Energy Board Act, 1998
  • Ontario Mental Health Foundation Act
  • Oversight of Health Facilities and Devices Act, 2017
  • Patient Restraints Minimization Act, 2001
  • Pay Equity Act
  • Personal Health Information Protection Act, 2004
  • Private Hospitals Act
  • Public Hospitals Act
  • Public Sector Labour Relations Transition Act, 1997
  • Public Sector Salary Disclosure Act, 1996
  • Quality of Care Information Protection Act, 2004
  • Regulated Health Professions Act, 1991
  • Residential Tenancies Act, 2006
  • Retirement Homes Act, 2010
  • Smoke-Free Ontario Act
  • Social Contract Act, 1993
  • Substitute Decisions Act, 1992
  • Tobacco Damages and Health Care Costs Recovery Act, 2009

Purpose
.
1 The purpose of this Act is to require the reporting of information about financial relationships that exist within Ontario’s health care system, including within health care research and education, and to enable the collection, analysis and publication of that information in order to,
.
(a) strengthen transparency in order to sustain and enhance the trust that patients have in their health care providers and in the health care system;
.
(b) provide patients with access to information that may assist them in making informed decisions about their health care;
.
(c) provide the Minister and others with information for the purposes of health system research and evaluation, planning and policy analysis; and
.
(d) provide for the collection, use and disclosure of personal information for these purposes.

Interpretation, “payor”
.
3 Any of the following persons is a payor for the purposes of this Act if the person provides a transfer of value to a recipient:
.
1. A manufacturer that sells a medical product under the manufacturer’s own name or under a trade-mark, design, trade name or other name or mark that is owned or controlled by the manufacturer and that fabricates, produces, processes, assembles, packages or labels the product, even if those tasks are performed by someone else on the manufacturer’s behalf.
.
2. A person who fabricates, produces, processes, assembles, packages or labels a medical product on behalf of a manufacturer described in paragraph 1.
.
3. A wholesaler, distributor, importer or broker that promotes or facilitates the sale of a medical product.
.
4. A marketing firm or person who performs activities for the purposes of marketing or promoting a medical product.
.
5. A person who organizes continuing education events for members of a health profession on behalf of a manufacturer described in paragraph 1.
.
6. A prescribed person or entity.
.
Reporting obligations
.
4 (1) Subject to subsection (2), a payor shall report to the Minister the information set out in subsection (5) with respect to the following transactions:
.
1. A transfer of value provided directly by a payor to a recipient.
.
2. A transfer of value provided indirectly by a payor to a recipient through an intermediary.

Schedule 4 is the most interesting part.

SCHEDULE 4
health sector payment transparency act, 2017

The Schedule enacts the Health Sector Payment Transparency Act, 2017.

The purpose of the Act, as set out in section 1, is to require the reporting of information about financial relationships that exist within Ontario’s health care system, including within health care research and education, and to enable the collection, analysis and publication of that information in order to, among other things, strengthen transparency. The Act requires that certain transactions be reported to the Minister who shall analyse and publish the information. The Act establishes a framework for inspections and other compliance mechanisms. The Act provides for periodic review by the Minister.

The above list are the Acts that would have been impacted by Bill 160. In total, it was a significant omnibus bill. A great piece of legislation in many ways, except that it was never actually implemented, as we will see later.

4. Ford Fully On Mass Vaccination Bandwagon

This is from April 18, 2020, which is just a week ago. Listen to 6:30 mark in the video. The man talks about taking blood from people who have already recovered from Coronavirus. Okay, if people are already recovering, why the push to rush out a vaccine.

At 6:50, this may just be a poor choice of wording, but we hear “not only a step towards developing a vaccine, but treating covid-19. Okay, is the vaccine not a treatment then?

It’s also interesting that when this group is pushed for specifics about reopening the Province, they continuously deflect with vague comments about “health and science”. And if you think it’s just Ontario that is pumping money into the vaccination agenda, consult the articles above in Section #1. Also, here are some more videos.

(Bill Gates predicts no more mass gathering until vaccine developed.

(See 1:30 mark in this, or original video). Trudeau claims that “normalcy will not return without a vaccine that is widely available, and that could be a very long way off”.

(From March 30, 2020 public announcement). The Government of Alberta is stating is may very well be a year to develop a vaccine.

Does anyone notice that they all seem to be pushing the same talking points? It’s all about pushing a vaccine, and keeping some form of restriction or lockdown until that happens.

5. Ford Gives Apotex A Shoutout

“Over the past few weeks, we’ve seen an overwhelming number of Ontario businesses join the fight against COVID-19, whether it’s re-tooling to manufacture vital supplies like hand sanitizer, masks, or ventilators, or delivering those supplies to our frontline health care workers and first responders,” said Doug Ford, Premier of Ontario, in a statement. “Companies like Apotex are showing the Ontario spirit by stepping up to the plate and offering to help. Working together, we will defeat COVID-19 and get through this crisis.”

Interesting bit of information is Premier Ford giving a shout out to Apotex, a GTA based pharmaceutical company. Without sidetracking too much, there is a rather convoluted story with Apotex, and here are some of the main points.

Apotex had been heavily involved in attempting to lobby the Federal Government into passing favourable legislation regarding intellectual property. There are many reports, and in fact a complaint had been filed due to the questionably nature of some of the lobbying. Barry Sherman and his wife Honey were murdered shortly after the investigation began.

Interestingly, there aren’t any lobbying reports after the December 2017 murder of the Shermans.

CapforCanada post a good article on the situation, and it’s well worth a read. The story is too long to address here, but it’s believed that this was murder, committed to keep quiet about illegal lobbying with the Trudeau and Morneau families.

In yet another twist, Apotex announced it will supply HYDROXYCHLOROQUINE, which is an anti-malaria drug, for clinical trials to combat coronavirus.

All of this is a huge aside, but it is interesting that Ford would single Apotex out by name, especially under the circumstances. He also hasn’t (to my knowledge) mentioned this drug as a potential cure, though he insists that a vaccine is necessary to return life to normal.

While Apotex lobbying on the Federal sphere may have stopped, it is a very different story Provincially.

This is just what’s on the record between Apotex and the Ontario Government. But sure, nothing to see here, people.

6. Bill 160 Never Actually Proclaimed

According to CanLII, Bill 160 wasn’t proclaimed (brought into force), as of May 29, 2019, which was a full 6 months after it had cleared in the Legislative Assembly. The Ontario Government “does” make reference to the passing of Bill 160, but adds in the all-important disclaimer: ONCE PROCLAIMED INTO FORCE

7. Ford Never Implemented Bill 160

Health.Sector.Payment.Transparency.Act20171123_Submission-on-Bill-160_IMC_Final
b160.accountability.ra_e

A law that would have made Ontario the first province in which drug companies were forced to publicly disclose their payments to doctors is in limbo with less than two months to go before the data collection was supposed to begin.

Premier Doug Ford’s Progressive Conservative government has not enacted the regulations that would bring into force the Health Sector Payment Transparency Act, legislation that was hailed as a major step toward openness in medical marketing when the former Liberal government passed it nearly a year ago.

Health Minister Christine Elliott’s office would not say whether the Tories intend to proceed with the transparency law or abandon it.

In the meantime, the legislation has been left to languish alongside other laws the Liberals passed but did not execute before they were swept out of office in June.

“We know, in many cases, the health sector did not feel that the prior government engaged in proper consultation when enacting legislation,” Hayley Chazan, the minister’s press secretary, said in an e-mailed statement that declined to answer specific questions about the transparency law. “That’s why our government is broadly consulting with partners in health care and reviewing all legislation that has not yet come into force as part of our efforts to develop a long-term transformational health strategy.”

The law would have led to the release of massive amounts of new data about how the pharmaceutical industry tries to influence the practice of medicine in the province.

How convenient it is that a law passed in 2017 was never actually implemented. This would have forced drug manufacturers and consultants to disclose how much money they had been spending in order to push their drugs to the public at large.

Ford claims (as did Wynne) that a delay is necessary in order to consult various parties and look for ways to best implement it. So, then why go through the time and expense of drafting and debating legislation BEFORE the consultations were done and the details worked out? Why is doing it AFTER the fact a better alternative?

Or, could this just be a way of “appearing” to clamp down on lobbyist influence, while still ensuring that is goes ahead nonetheless? Doesn’t seem like a populist thing to do.

8. Pharma Lobbying Of Ontario Gov’t

Of course, this is nowhere near all of them. Does it paint a clearer picture? The Ontario Government is on the receiving end of lobbying by the drug industry. But because Bill 160 wasn’t implemented, we won’t know if any money has changed hands.

9. Ontario Gov’t And Pharma Lobbying

Could this be the real reason Bill 160 was never implemented? All of these lobbying records look back enough on the surface. However, if money changed hands in order for certain drugs to be approved, or be sold in certain places, it ups the sleaziness considerably.

Kathleen Wynne passed Bill 160 in late 2017. She could have easily implemented it. So could have Doug Ford when he took power. Both had majority governments.

Keep in mind, this is not an exhaustive list of the drug lobbying that is going on in the Ontario Legislature. There is much more, and the above is just a sample of it.

Now, with this so-called “coronavirus epidemic”, Ford seems very interested in pushing to have a vaccine developed. Could the influence-peddling of Big Pharma have something to do with that?

One Reply to “CV #11: Pharma Lobbying In Ontario — Good Thing Bill 160 Was Never Implemented”

  1. It’s sad to see this happen.

    The only reason I can give for not actually implementing is a deliberate effort to “appear” to be against drug lobbying, while ensuring it continues.

Leave a Reply